Loading…
Loading…
CEFs fell this week: 7 of 26 sectors rose on price (average -0.88%) and 12 of 26 on NAV (average -0.30%); munis led while convertibles lagged. DMA announced a buyback and +2.2% distribution raise as it entered its term measurement period; ASGI's rights offering was about 34% subscribed at $19.28. At the fund level, NMS (+5.11%) led on price and KF fell the most (-15.39%); on NAV, BGR (+4.62%) led while KF dropped -16.09%.
One year after Biohaven's first TRAP degrader, BHV-1400, was highlighted in the Kidney Week opening plenary, Biohaven's second TRAP degrader for kidney disease expands its Yale-licensed platform into a growing nephrology franchise BHV-1420 is an investigational TRAP™ extracellular protein degrader. It is designed to bind anti-PLA2R autoantibodies, the main driver of disease in most patients with membranous nephropathy, directing them to the liver for degradation without immunosuppression.
Ono will obtain an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degraders in Japan, South Korea, Taiwan, and ASEAN member states, led by BHV-1300 and including certain next-generation follow-on IgG degraders. Biohaven will receive up to $100 million in near-term payments, including $80 million upfront and eligible to receive another $20 million upon a milestone achievement anticipated within a year, and royalties of approximately twenty percent on net sales by Ono in the licensed territory.
Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), a leading international forum for early-phase oncology drug development. First-in-class FGFR3 ADC: BHV-1530 is a first-in-class potential FGFR3-directed antibody-drug conjugate incorporating Biohaven's proprietary TopoIx payload, that has shown early clinical activity with a differentiated and tolerable safety profile.
BlackRock Virginia Municipal Bond Trust (NYSEAMERICAN:BHV - Get Free Report)'s share price crossed below its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $12.66 and traded as low as $12.47. BlackRock Virginia Municipal Bond Trust shares last traded at $12.47, with a volume of 975
Biohaven Ltd. maintains a Buy rating, driven by pivotal trial progress in protein degraders and a key licensing deal for its Kv7 platform with SK Biopharmaceuticals. BHVN-1300's phase 3 for Graves' disease is underway; BHV-1400's phase 3 for IgA nephropathy is set to start in H2 2026. Opakalim [BHV-7000] for refractory focal epilepsy is fully enrolled in phase 2/3, with topline data expected in H2 2026 and a $350M upfront SK Biopharmaceuticals deal secured.
First extracellular protein degraders in the clinic demonstrate rapid and robust pharmacodynamic effects and compelling safety in nearly 200 individuals dosed, Phase 3 trial underway Positive clinical biomarker and patient data presented from Biohaven's extracellular degrader platform demonstrated deep, rapid, selective lowering of disease-driving antibodies with BHV-1300 in Graves' disease and BHV-1400 IgA Nephropathy, supporting advancement toward multiple registrational programs. Initiated pivotal Phase 3 study for BHV-1300 in Graves' disease with plans to initiate pivotal Phase 3 study for BHV-1400 in IgAN in 2H 2026.
Biohaven also announces new clinical supply agreement with Regeneron to evaluate BHV-1530 in combination with cemiplimab (Libtayo®) Early clinical activity observed: Phase 1 dose-escalation data show early tumor reductions in patients with Fibroblast Growth Factor Receptor (FGFR)3-altered and wild-type overexpressing tumors. Signal activity including confirmed partial responses in heavily pretreated patients in multiple tumor types.